Crizotinib

Contraindicated

Crizotinib Ketoconazole Topical Extina® Foam Increased crizotinib exposure, increased ketoconazole exposure and an increased risk of QT interval prolongation Details

Major

Crizotinib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Crizotinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Crizotinib Clindamycin ANTIROBE Explained Increased exposure of the CYP3A substrate Details Crizotinib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Crizotinib Sertraline Explained An increased risk of QT interval prolongation Details Crizotinib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Crizotinib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Crizotinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Crizotinib Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Crizotinib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Crizotinib Apixaban Eliquis Explained Increased apixaban exposure Details Crizotinib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Crizotinib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Crizotinib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Crizotinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Crizotinib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Crizotinib Atenolol Tenormin Explained An increased risk of bradycardia Details Crizotinib Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Crizotinib Azithromycin AzaSite An increased risk of QT interval prolongation Details Crizotinib Acebutolol Sectral® An increased risk of bradycardia Details Crizotinib Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Crizotinib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Crizotinib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Crizotinib Anagrelide Agrylin An increased risk of QT interval prolongation Details Crizotinib Axitinib Inlyta Increased exposure of the CYP3A substrate Details Crizotinib Bedaquiline Sirturo An increased risk of QT interval prolongation Details Crizotinib Betaxolol Betoptic S An increased risk of bradycardia Details Crizotinib Betaxolol Ophthalmic Betoptic® An increased risk of bradycardia Details Crizotinib Bisoprolol Zebeta® An increased risk of bradycardia Details Crizotinib Bosutinib Bosulif Increased bosutinib exposure Details Crizotinib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Crizotinib Brigatinib Alunbrig Increased brigatinib exposure Details Crizotinib Chloroquine Aralen® An increased risk of QT interval prolongation Details Crizotinib Clindamycin Injection ANTIROBE Increased exposure of the CYP3A substrate Details Crizotinib Clindamycin Topical C/T/S® Increased exposure of the CYP3A substrate Details Crizotinib Clindamycin Vaginal Cleocin Increased exposure of the CYP3A substrate Details Crizotinib Clonidine Transdermal Patch Catapres An increased risk of bradycardia Details Crizotinib Cobimetinib Cotellic Increased exposure of the CYP3A substrate Details Crizotinib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details